Medacta Group SA · SIX:MOVE

Medacta Group SA — H1 2022 Earnings Presentation

11 slides from Medacta Group SA's earnings presentation, Jul 29, 2022

  1. Slide 1: 1H 2022 Preliminary Unaudited Top-Line Figures

    1H 2022 Preliminary Unaudited Top-Line Figures 29 July 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou

  3. Slide 3: Francesco Siccardi, CEO and Corrado Farsetta, CFO

    FRANCESCO SICCARDI CORRADO FARSETTA Chief Executive Officer Chief Financial Officer 1H 2022 Preliminary Unaudited Top-Line Figures

  4. Slide 4: 1H 2022 Highlights

    1H 2022 Highlights  1H 2022 revenue increased to Euro 211.3 million, or 19.0% (14.6% at constant currency) from 1H 2021  Significant customer acquisition, salesforce expansion and product introduction drove the growth that was limited by pandemic restrictions and hospital staffing shortages in Aus

  5. Slide 5: Revenue Bridge by Product Line

    1H 2022 Revenue1 Bridge by Product Line 11.1% 16.1% 35.6% 16.0% 14.6% 19.0% 19.8; 9% (€m, %) 12.9; 6% (€m) 101.4; 48% 77.2; 37% 2 Hip Knee Extremities Spine  Hip: growth driven by the AMIS® strategy, supported by further adoption of the Bikini technique, and the roll-out of new products  Knee: goo

  6. Slide 6: Revenue Bridge by Geographic Area

    1H 2022 Revenue1 Bridge by Geographic Area 22.0% 10.8% 3.7% 31.8% 14.6% 19.0% 7.9; 4% (€m, %) (€m) 44.8; 21% 94.4; 45% 64.2; 30% Europe NA APAC ROW In 1H 2022 the geographic mix from prior period shows a shift from APAC to Europe mainly due to Covid-19 restrictions in Australia  Europe: solid growt

  7. Slide 7: 1H 2019-2022 True Growth beyond a Mere Recovery

    1H 2019-2022 True Growth beyond a Mere Recovery 1H 2019-2022 Revenue1 Trend by Product Line 101.4 (€m) 88.4 82.9 77.2 68.9 REVENUE CAGR 63.4 53.7 1H 2019-2022 47.3 HIP 6.3% KNEE 11.9% 16.6 19.8 SPINE 21.9% 10.9 12.5 9.1 12.9 EXTREMITIES 44.5% 4.2 6.1 Total 10.9% 1H19 1H20 1H21 1H22 Total 151.6 134.8

  8. Slide 8: NextAR AR Surgical Platform

    NextAR™ AR Surgical Platform  Following 1,000 NextAR™ surgeries performed worldwide in the limited market release phase, we reached 100 NextAR™ platforms in the market. This milestone was driven by the full market release of the NextAR™ shoulder application in May 2022  In June 2022, NextAR™ furth

  9. Slide 9: 2022 Outlook

    2022 Outlook  Thanks to the positive business performance of the first semester, full-year revenue is expected in the top end of the original guidance range of Euro 400 million to Euro 414 million, at constant currency  In light of the current macroeconomic and geopolitical situation and initiativ

  10. Slide 10: Q&A

    Q&A 1H 2022 Preliminary Unaudited Top-Line Figures

  11. Slide 11: Medacta International

    Adedacta International

Medacta Group — H1 2022 Earnings Presentation on 6ix